Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniela Pietra

Showing results (31-40 of 92) with videos related to

Pageof 10
Sort By:
Blood|August 6, 2005
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2Robert Kralovics, Soon-Siong Teo, Andreas S Buser, et al.
Cancer|September 26, 2006
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disordersElisa Rumi, Francesco Passamonti, Daniela Pietra, et al.
American Journal of Hematology|September 29, 2011
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasmElisa Rumi, Ashot Harutyunyan, Chiara Elena, et al.
Blood|November 7, 2007
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disordersDaniela Pietra, Sai Li, Angela Brisci, et al.
Haematologica|January 14, 2011
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasmsDaniela Pietra, Angela Brisci, Elisa Rumi, et al.
Haematologica|September 16, 2008
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patientsFrancesco Passamonti, Elisa Rumi, Luca Arcaini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 24, 2008
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromesMatteo Giovanni Della Porta, Luca Malcovati, Emanuela Boveri, et al.
Blood|December 24, 2005
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disordersFrancesco Passamonti, Elisa Rumi, Daniela Pietra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2007
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipationElisa Rumi, Francesco Passamonti, Matteo G Della Porta, et al.
British Journal of Haematology|December 15, 2005
Genetic and clinical heterogeneity of ferroportin diseaseL Cremonesi, Laura Cemonesi, Gian Luca Forni, et al.
Pageof 10

Showing results (31-40 of 92) with videos related to

Sort By:
Pageof 10
Blood|August 6, 2005
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2Robert Kralovics, Soon-Siong Teo, Andreas S Buser, et al.
Cancer|September 26, 2006
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disordersElisa Rumi, Francesco Passamonti, Daniela Pietra, et al.
American Journal of Hematology|September 29, 2011
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasmElisa Rumi, Ashot Harutyunyan, Chiara Elena, et al.
Blood|November 7, 2007
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disordersDaniela Pietra, Sai Li, Angela Brisci, et al.
Haematologica|January 14, 2011
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasmsDaniela Pietra, Angela Brisci, Elisa Rumi, et al.
Haematologica|September 16, 2008
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patientsFrancesco Passamonti, Elisa Rumi, Luca Arcaini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 24, 2008
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromesMatteo Giovanni Della Porta, Luca Malcovati, Emanuela Boveri, et al.
Blood|December 24, 2005
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disordersFrancesco Passamonti, Elisa Rumi, Daniela Pietra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2007
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipationElisa Rumi, Francesco Passamonti, Matteo G Della Porta, et al.
British Journal of Haematology|December 15, 2005
Genetic and clinical heterogeneity of ferroportin diseaseL Cremonesi, Laura Cemonesi, Gian Luca Forni, et al.
Pageof 10